NCT04324164

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 800 (estimated)
• Sponsor: Hunan Province Tumor Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China

Detailed description

inclusion criteria Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer EGFR G719X, exon 20 insert mutation without any anti-cancer treatment history

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Third-generation EGFR-TKI	Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.
DRUG	EGFR-TKI	All EGFR-TKI

Timeline

• Start date: 2020-03-24
• Primary completion: 2025-12-24
• Completion: 2027-12-24
• First posted: 2020-03-27
• Last updated: 2025-01-27

Locations

1 site across 1 country: China